Elevation Oncology Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
38
- Latest Deal Type
-
M&A
- Investors
-
1
Elevation Oncology General Information
Description
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
Contact Information
Website
www.elevationoncology.comCorporate Office
- 101 Federal Street
- Suite 1900
- Boston, MA 02110
- United States
Corporate Office
- 101 Federal Street
- Suite 1900
- Boston, MA 02110
- United States
Elevation Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 23-Jul-2025 | Completed | Clinical Trials - Phase 2 | |||
| 4. 2PO | 09-Jun-2023 | Completed | Generating Revenue | |||
| 3. IPO | 25-Jun-2021 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 12-Nov-2020 | $65M | $95M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 16-Jan-2020 | $30M | $30M | Completed | Startup |
Elevation Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Elevation Oncology Comparisons
Industry
Financing
Details
Elevation Oncology Competitors (84)
One of Elevation Oncology’s 84 competitors is Instil Bio, a Formerly VC-backed company based in Dallas, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Instil Bio | Formerly VC-backed | Dallas, TX | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Obsidian Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA |
Elevation Oncology Patents
Elevation Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026226759-A1 | Anti-her3 antibody-drug conjugates and uses thereof | Pending | 24-Apr-2025 | ||
| EP-4304636-A1 | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions | Inactive | 11-Mar-2021 | ||
| US-20220288204-A1 | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions | Inactive | 11-Mar-2021 | ||
| WO-2022192534-A1 | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions | Inactive | 11-Mar-2021 | ||
| US-20140079703-A1 | Combination therapies comprising anti-erbb3 agents | Active | 30-Aug-2012 | C07K16/32 |
Elevation Oncology Signals
Elevation Oncology Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| Boxer Capital | Corporate Venture Capital | Minority | ||
| Driehaus Capital Management | Corporation | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority |
Elevation Oncology Investments (1)
Elevation Oncology’s most recent deal was a Corporate Asset Purchase with Merrimack Pharmaceuticals (anti-HER3 programs). The deal was made on 01-Jul-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Merrimack Pharmaceuticals (anti-HER3 programs) | 01-Jul-2019 | Corporate Asset Purchase | Buildings and Property |
Elevation Oncology ESG
Risk Overview
Risk Rating
Updated August, 31, 2025
38.28 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
Elevation Oncology FAQs
-
When was Elevation Oncology founded?
Elevation Oncology was founded in 2019.
-
Where is Elevation Oncology headquartered?
Elevation Oncology is headquartered in Boston, MA.
-
What is the size of Elevation Oncology?
Elevation Oncology has 38 total employees.
-
What industry is Elevation Oncology in?
Elevation Oncology’s primary industry is Drug Discovery.
-
Is Elevation Oncology a private or public company?
Elevation Oncology is a Private company.
-
What is Elevation Oncology’s current revenue?
The current revenue for Elevation Oncology is .
-
How much funding has Elevation Oncology raised over time?
Elevation Oncology has raised $235M.
-
Who are Elevation Oncology’s investors?
Aisling Capital, BVF Partners, Boxer Capital, Driehaus Capital Management, and Janus Henderson Investors are 5 of 13 investors who have invested in Elevation Oncology.
-
Who are Elevation Oncology’s competitors?
Instil Bio, Poseida Therapeutics, Kite Pharma, Obsidian Therapeutics, and Allogene Therapeutics are some of the 84 competitors of Elevation Oncology.
-
When was Elevation Oncology acquired?
Elevation Oncology was acquired on 23-Jul-2025.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process